1
The use of SIS has been reported before in a number of various animals and in human subjects, but in this series the authors have used a double patch in 3 of the 8 individuals based on the preop- erative size of the bladder in order to achieve a sufficient volume. Regardless of the size of the patch, there was no difference in total bladder ca- pacity, maximum detrusor pressure or compliance after the 1-year observation period. Promising re- sults have been noted before with polyglycolic acid and other materials, as well as with seeded and nonseeded scaffolds, only to discover later that these patches contracted, capacity diminished and pressures increased, leading to the necessity of an enteric augment. Therefore, as someone who has seen a multitude of long-term issues associated with intestinal augments, I am encouraged with these intermediate results. I trust the authors will continue their meticulous followup of this cohort for several more years to determine if these moderate- term good results are maintained. Whether non- seeded scaffolds are a better long-term source than cell seeded constructs remains to be seen, but at least at this juncture the technology reported here is promising. Stuart B. Bauer Department of Urology Boston Children’s Hospital Harvard Medical School Boston, Massachusetts REPLY BY AUTHORS We will continue the careful followup of this cohort to determine the long-term outcomes. Although this nonseeded scaffold is easy to use in clinical practice, we also note that any kind of patch is likely to shrink, leading to reduced capacity and increased pressure in the long term. More cases are being accumulated at our department, and we look forward to reporting the long-term results of this technology in the future. 8 CYSTOPLASTY AUGMENTATION FOR NEUROGENIC BLADDER USING SMALL INTESTINAL SUBMUCOSA 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 Dochead: New Technology and Techniques DIS 5.2.0 DTD ĸ JURO11353_proof ĸ 15 May 2014 ĸ 7:24 pm ĸ EO: JU-13-2154

Reply by Authors

  • Upload
    dodung

  • View
    218

  • Download
    0

Embed Size (px)

Citation preview

8 CYSTOPLASTY AUGMENTATION FOR NEUROGENIC BLADDER USING SMALL INTESTINAL SUBMUCOSA

799800801802803804805806807808809810811812813814815816817818819820821822823824825826827828829

830831832833834835836837838839840841842843844845

The use of SIS has been reported before in anumber of various animals and in human subjects,but in this series the authors have used a doublepatch in 3 of the 8 individuals based on the preop-erative size of the bladder in order to achieve asufficient volume. Regardless of the size of thepatch, there was no difference in total bladder ca-pacity, maximum detrusor pressure or complianceafter the 1-year observation period. Promising re-sults have been noted before with polyglycolic acidand other materials, as well as with seeded andnonseeded scaffolds, only to discover later thatthese patches contracted, capacity diminished andpressures increased, leading to the necessity of anenteric augment. Therefore, as someone who has

Dochead: New Technology and Techniques DIS 5.2.0 DTD �

seen a multitude of long-term issues associatedwith intestinal augments, I am encouraged withthese intermediate results. I trust the authors willcontinue their meticulous followup of this cohort forseveral more years to determine if these moderate-term good results are maintained. Whether non-seeded scaffolds are a better long-term source thancell seeded constructs remains to be seen, but atleast at this juncture the technology reported hereis promising.

Stuart B. BauerDepartment of Urology

Boston Children’s Hospital

Harvard Medical School

Boston, Massachusetts

846847848 849850851852853

REPLY BY AUTHORS

We will continue the careful followup of this capacity and increased pressure in the long

854855856857

cohort to determine the long-term outcomes.Although this nonseeded scaffold is easy to usein clinical practice, we also note that any kindof patch is likely to shrink, leading to reduced

term. More cases are being accumulated at ourdepartment, and we look forward to reportingthe long-term results of this technology in thefuture.

858

859860

JURO11353_proof � 15 May 2014 � 7:24 pm � EO: JU-13-2154